We caught up with Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) to discuss the results of the phase 2B study of roflumilast cream in adults with chronic plaque psoriasis (ClinicalTrials.gov identifier: NCT03638258).
1. What are the limitations of current topical therapies for chronic plaque psoriasis? (0:06)
2. What is the mechanism of action of roflumilast and what are its advantages compared with other PDE4 inhibitors used in dermatology? (1:03)
3. Could you tell us a little about the ARQ-151 201 study and its efficacy and safety findings? (1:47)
4. Tell us more about the effect of roflumilast on patient-reported outcomes. (2:48)
5. What were the limitations of this study and what future studies are planned? (3:49)
Disclosures: Dr Gold Stein reports the following relationships – Arcutis: Investigator, Advisor; Dermavant: Investigator, Advisor; Leo Pharma: Investigator, Advisor; Ortho Derm: Investigator, Advisor; and Pfizer: Investigator, Advisor, Speaker.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the EADV 2020 Virtual Congress.
Share this Video
Related Videos In Psoriasis
Leon Kircik, AAD VMX 2021: Roflumilast Foam in Scalp and Body Psoriasis
Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai, New York, NY, USA) kindly took the time to speak with us about the results from the recent phase 2b study investigating roflumilast foam in the treatment of scalp and body psoriasis. His abstract entitled ‘Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A […]
Kim Papp, AAD VMX 2021: Secukinumab PURE Study
We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis. The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over […]
Siew Eng Choon, AAD VMX 2021: Unmet Needs in Generalised Pustular Psoriasis
It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the current unmet needs in the treatment of generalised pustular psoriasis (GPP). Disclosures: Dr Siew Eng Choon has received honoraria for serving as a consultant, advisory board member, and/or speaker for AbbVie, Boehringer Ingelheim, Janssen, Leo, Eli Lilly, Leo, Novartis, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!